🔵 RESEARCH
Zambian pilot tests ultrasound-only diagnosis of tuberculous pleural effusion
A cross-sectional pilot in Zambia evaluated whether sonographic features alone can diagnose tuberculous pleural effusion where invasive testing is unavailable.
If validated at scale, ultrasound-only TPE diagnosis expands the addressable market for portable ultrasound vendors in TB-endemic regions. Watch for accuracy metrics versus gold standard before reading too much into a single-site pilot.
Tropical medicine & international health : TM & IH · 2026-05-07
Read more →
🔵 RESEARCH
Multicenter trial builds AI to flag valve disease on routine chest CT
A prospective multicenter study registered on ClinicalTrials.gov will develop and validate a deep learning model to screen valvular heart disease from non-contrast chest CT.
Opportunistic cardiac screening from existing CT volume could pressure dedicated echo workflows and create a new AI revenue line inside radiology. Registration is not evidence — sensitivity against echo gold standard will decide whether this becomes routine.
🟢 FUNDING
Roche to acquire PathAI for up to $1.05 billion
Roche agreed to buy digital pathology firm PathAI for up to $1.05 billion, integrating its AI tools into cancer diagnostic workflows.
The deal validates digital pathology as a billion-dollar category and forces Philips and Leica Biosystems to accelerate AI roadmaps or cede oncology workflow ground. The 'up to' structure leaves upfront value and milestones unclear — scrutinise terms before pricing comps.
🔵 RESEARCH
JUM paper refines ML methods for deployable ultrasound radiomics
Journal of Ultrasound in Medicine published methodological refinements aimed at making machine-learning ultrasound radiomics workflows practical to deploy clinically.
Standardised deployment methods reduce friction for embedding radiomics into GE, Philips and Siemens platforms — but academic refinements rarely reach the floor without DICOM integration, vendor partnerships and tech training. Wait for commercial reference sites.
Journal of Ultrasound in Medicine · 2026-05-07
Read more → (paywall)
🔴 REGULATORY
RIVANNA clears Accuro XV musculoskeletal ultrasound with FDA 510(k)
RIVANNA received FDA 510(k) clearance for its Accuro XV musculoskeletal ultrasound imaging system.
Vertical-specific clearances like this signal ultrasound AI fragmenting into niche markets where point players can avoid head-on competition with GE and Philips. Adoption beyond specialty MSK and sports medicine clinics will require workflow changes most hospitals are not ready for.
Google News: ultrasound AI FDA 510k cleared · Fri, 08 Ma
Read more →
🔵 RESEARCH
Brain imaging identifies distinct migraine subtypes
Researchers used neuroimaging to identify distinct migraine subtypes, suggesting imaging biomarkers could differentiate headache pathophysiology.
Subtyping creates a pathway to precision migraine therapeutics and premium-priced diagnostic positioning, but routine imaging-guided headache workups face reimbursement and capacity barriers. Adoption hinges on payers crediting imaging with better outcomes than empirical treatment.
Medical Xpress — Health Research · Fri, 08 Ma
Read more →
🩺 EDITOR’S TAKE — FOR CLINICIANS
Watch the opportunistic-screening trend: AI now mining routine chest CTs for valve disease, brain MRIs for migraine subtypes, and ultrasound for TB. The diagnostic question is shifting from what you ordered to what else the scan can tell you.
📊 EDITOR’S TAKE — FOR INVESTORS
Roche's $1.05B PathAI deal sets a clear comp for AI-native diagnostics and pressures Philips and Leica to respond. Expect more pharma-led acquisitions of platforms feeding oncology pipelines, and premium multiples for vertical-specific AI like RIVANNA's MSK play.
🏭 EDITOR’S TAKE — FOR INDUSTRY
Ultrasound AI is fragmenting into vertical niches — MSK, TB, radiomics — while pathology consolidates under Big Pharma. OEMs face a two-front problem: defend horizontal platforms against point solutions while integrating embedded AI fast enough to keep enterprise customers.